HilleVax, Inc. (NASDAQ:HLVX) Receives Consensus Rating of “Hold” from Analysts

Shares of HilleVax, Inc. (NASDAQ:HLVX) have earned a consensus rating of “Hold” from the six research firms that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $3.00.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $2.00 target price on shares of HilleVax in a research report on Monday, March 31st.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of HLVX. Two Sigma Advisers LP increased its stake in shares of HilleVax by 76.8% in the fourth quarter. Two Sigma Advisers LP now owns 41,200 shares of the company’s stock valued at $85,000 after buying an additional 17,900 shares during the period. Two Sigma Investments LP lifted its position in shares of HilleVax by 76.3% in the 4th quarter. Two Sigma Investments LP now owns 55,535 shares of the company’s stock worth $115,000 after purchasing an additional 24,039 shares during the period. Stonepine Capital Management LLC acquired a new stake in shares of HilleVax during the fourth quarter worth $274,000. Millennium Management LLC boosted its position in HilleVax by 59.6% during the fourth quarter. Millennium Management LLC now owns 411,820 shares of the company’s stock valued at $852,000 after acquiring an additional 153,815 shares during the last quarter. Finally, Lightspeed Management Company L.L.C. acquired a new stake in HilleVax during the 4th quarter worth about $4,847,000. 86.42% of the stock is owned by institutional investors.

HilleVax Price Performance

Shares of NASDAQ:HLVX opened at $1.42 on Monday. HilleVax has a one year low of $1.34 and a one year high of $16.31. The company has a market cap of $70.72 million, a price-to-earnings ratio of -0.46 and a beta of 0.76. The firm has a 50 day simple moving average of $1.77 and a 200 day simple moving average of $1.85.

HilleVax (NASDAQ:HLVX) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.02). As a group, analysts expect that HilleVax will post -2.64 EPS for the current year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.